ASX Share rice
Sun 16 May 2021 - 12:29:am (Sydney)

IPD Share Price

IMPEDIMED LIMITEDIPDHealth Care Equipment & Services

IPD Company Information

Name:

ImpediMed Limited

Sector:

Healthcare

Industry:

Medical Devices

GIC Industry:

Health Care Equipment & Supplies

GIC Sub Industry:

Health Care Equipment

Address:

50 Parker Court Pinkenba QLD Australia 4008

Phone:

61 7 3860 3700

Full Time Employees:

69

MD, CEO, Pres & Exec. Director:

Mr. Richard Carreon

Sr. VP of Operations & Strategic Planning:

Mr. David Michae Adams B.Sc., J.D., BSc

Chief Technology Officer:

Mr. Shashi Tripathi

Sr. VP of R&D and Technology:

Mr. Dennis Schlaht

Sr. VP of Medical Affairs:

Ms. Catherine Kingsford

Chief Financial Officer:

Mr. Timothy Cruickshank

Sr. VP of Corp. & Strategic Devel.:

Mr. Michael John Bassett

VP of HR:

Ms. Nancy T. Deisinger

Chief Medical Officer:

Dr. Frank A. Vicini

Company Sec.:

Ms. Leanne Ralph BBus, ACIS, AAICD

Company Overview:

ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.

IPD Share Price Information

Shares Issued:

1.49B

Market Capitalisation:

$179M

Revenue (TTM):

$6.48M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.064

Profit Margin:

-2.9113

Operating Margin (TTM):

$-3.55

Return On Assets (TTM):

$-0.51

Return On Equity (TTM):

$-0.88

Quarterly Revenue Growth (YOY):

0.262

Gross Profit(TTM):

$4.06M

Diluted Earnings Per Share (TTM):

$-0.022

IPD CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-2,161,000

Change To Liabilities:

$-58,000

Total Cashflow From Investing Activities:

$-2,161,000

Net Borrowings:

$-413,000

Net Income:

$-21,377,000

Total Cash From Operating Activities:

$-19,218,000

Depreciation:

$464K

Change To Inventory:

$257K

Change To Account Receivables:

$-256,000

Sale Purchase Of Stock:

$33.25M

Capital Expenditures:

$91K

IPD Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-21,329,000

Net Income:

$-21,377,000

Gross Profit:

$4.06M

Operating Income:

$-21,329,000

Other Operating Expenses:

$4.30M

Interest Expense:

$-39,000

Income Tax Expense:

$48K

Total Revenue:

$5.74M

Cost Of Revenue:

$1.68M

IPD Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$3.89M

Total Liabilities:

$5.70M

Total Stockholder Equity:

$27.36M

Other Current Liabilities:

$616K

Total Assets:

$33.06M

Common Stock:

$250.56M

Other Current Assets:

$408K

Retained Earnings:

$-250,061,000

Other Liabilities:

$87K

Good Will:

$2.64M

Cash:

$19.66M

Total Current Liabilities:

$5.11M

Property - Plant & Equipment:

$1.02M

Net Tangible Assets:

$20.84M

Long-Term Investments:

$77K

Total Current Assets:

$25.45M

Net Receivables:

$4.52M

Short-Term Investments:

$7.61M

Inventory:

$864K

Accounts Payable:

$1.91M

Short-Term Investments:

$7.61

Non Current Liabilities Total:

$594K

IPD Share Price History

IPD News

08 Apr, 2021
We can readily understand why investors are attracted to unprofitable companies. By way of example, ImpediMed ( ASX:IPD...
29 Jan, 2021
It is a pleasure to report that the ImpediMed Limited ( ASX:IPD ) is up 37% in the last quarter. But that doesn't...
25 Nov, 2020
Rick Carreon has been the CEO of ImpediMed Limited (ASX:IPD) since 2012, and this article will examine the executive's...
09 Jun, 2020